Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein. It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)) and aims...
Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada
Diex Recherche Joliette Inc., Joliette, Quebec, Canada
DIEX Recherche Victoriaville, Victoriaville, Quebec, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.